| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Senomyx, Inc. |
| 11099 North Torrey Pines Road, La Jolla, CA 92037 * (858) 646-8300 |
| Business Description | The company is designing and assembling a proprietary technology platform to enhance and industrialize the discovery process and overcome many of the limitations of traditional discovery programs for new flavor and fragrance molecules. |
|
Filing Information IPO has been | |||
| To Trade As | SNMX (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/21/2001 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $80,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Deutsch Banc Alex. Brown | Lead Manager | (410) 727-1700 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-4850 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1999 | 12/31/2000 | |||||
| Revenues | - | - | - | 0.000 | 0.000 | - | - |
| Income from Oper. | - | - | - | -1.423 | -11.444 | - | - |
| Net Income | - | - | - | -1.433 | -10.745 | - | - |
| E.P.S | - | - | - | -1.040 | -5.020 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.96 | - | - | ||||
| Cash Flow - Inv. | -12.76 | - | - | ||||
| Cash Flow - Fin. | 14.93 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/2000 | Financial Ratios | ||||
| Total Assets | 26.48 | Current Assets | 14.89 | Current Ratio | 5.85 |
| Total Liab. | 2.55 | Current Liab. | 2.55 | Debt Ratio | 9.61% |
| Total Equity | 23.94 | Working Cap. | 12.35 | Debt to Equity Ratio | 0.11 |
| Cash | 7.26 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for designing and assembling an integrated technology platform, acquiring and licensing other technologies and proprietary rights, carrying out a molecule discovery process, capital expenditures and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Morrison & Foerster |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Bay City Capital, L.L.C. | 15.00 | |
| Entities affiliated with Domain Associates, L.L.C. | 11.70 | |
| Entities affiliated with Prospect Venture Partners, L.P. | 10.10 | |
| Entities affiliated with Kingsbury Associates, L.P. | 8.30 | |
| Aurora Biosciences Corporation | 5.70 | |
| Rho Management Trust I | 5.10 | |
| Incyte Genomics, Inc. | 5.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||